A Digital Health Platform for Pancreatitis Management and Physician-Patient Collaboration

Table of Contents

• 1.Executive Summary3
• 2.The Pancreatitis Burden — Epidemiology & Clinical Impact3
• 3.The Digital Health Imperative4
• 4.Critical Gaps in Current Pancreatitis Care5
• 5.PancreaTrack AI — Platform Overview5
• 6.Core Clinical Features6
• 7.The PERT Enzyme Tracker7
• 8.Verified Physician Portal & Care Coordination8
• 9.AI-Powered Feature Suite (Meal Analysis, Trigger Finder, Summaries, Doc Q&A)8
• 10.Data Privacy, Security & Compliance10
• 11.Research Partnership Opportunities10
• 12.Comparative Landscape11
• 13.Business Model & Platform Valuation11
• 14.Conclusion & Call to Action12
• 15.References13

1Executive Summary

Pancreatitis — both acute and chronic — represents one of the most complex, costly, and underserved conditions in gastroenterology. Patients live with unpredictable pain, dietary restriction, enzyme replacement dependency, and a significantly diminished quality of life, often with minimal structured support between clinical appointments.

PancreaTrack AI is a disease-specific digital health platform purpose-built for individuals living with pancreatitis. Unlike generic symptom trackers or broad nutritional apps, every feature within PancreaTrack AI has been engineered around the clinical realities of pancreatitis management: fat-triggered pain, pancreatic enzyme replacement therapy (PERT), flare pattern recognition, exocrine and endocrine insufficiency monitoring, and verified physician-to-patient care communication.

This white paper presents the clinical rationale for PancreaTrack AI, describes its core feature set, outlines the physician portal architecture, and identifies opportunities for research collaboration, institutional partnership, and quality improvement initiatives.

2The Pancreatitis Burden

Pancreatitis carries a substantial and growing clinical and economic burden in the United States and globally. The disease exists on a spectrum from acute single-episode illness to debilitating chronic disease with systemic complications.

Beyond hospitalization metrics, chronic pancreatitis is associated with severely impaired health-related quality of life — in some validated assessments, comparable to that of patients with end-stage organ failure. Pain is the predominant symptom in over 80% of patients with chronic disease and is often refractory to standard analgesic protocols. Nutritional deficiency, steatorrhea, and metabolic complications compound the clinical picture significantly.

3The Digital Health Imperative

The shift toward patient-driven digital health management is no longer a trend — it is a documented behavioral reality with measurable clinical impact. The evidence for integrating disease-specific mobile health tools into chronic disease management is substantial and growing across every major specialty.

3.1 Patients Prefer Digital Tools for Chronic Condition Management

A 2022 survey by Rock Health found that 7 in 10 patients with chronic conditions prefer using a dedicated digital tool to manage their illness over relying solely on periodic clinical appointments. Among patients who actively use health-tracking apps, medication adherence improves by up to 40%, and self-reported health literacy scores increase significantly — both factors that directly influence clinical outcomes in complex conditions like pancreatitis.

3.2 The 99% Problem in Chronic Disease Care

A patient with chronic pancreatitis who attends monthly gastroenterology appointments spends fewer than 0.3% of their waking hours in a clinical setting. The remaining 99.7% is self-managed — without clinical oversight, structured data capture, or direct access to informed guidance. This asymmetry is the fundamental challenge of chronic disease management, and it is precisely the gap that disease-specific digital health platforms are designed to address.

3.3 The Physician Data Gap

Clinical studies on patient recall accuracy consistently demonstrate that pain score recall degrades rapidly — patients asked to reconstruct their pain experience over the prior two weeks underestimate peak pain by an average of 1.5–2 points on a 10-point scale (Stone et al., Pain, 2004). In pancreatitis, where treatment decisions hinge on frequency and severity of pain episodes, this recall inaccuracy translates directly into suboptimal clinical decisions. Continuous, timestamped app-based logging eliminates this variable entirely.

4Critical Gaps in Current Pancreatitis Care

Despite its significant burden, pancreatitis management suffers from a series of well-documented structural gaps that impair clinical outcomes and patient wellbeing.

3.1 The Data Desert Between Appointments

The average gastroenterology appointment lasts fewer than 15 minutes. Patients with chronic pancreatitis are typically seen every 4–12 weeks. In that interval, they experience hundreds of meals, dozens of enzyme dosing decisions, and often multiple pain episodes — none of which are systematically captured or communicated to their clinician. Treatment decisions are therefore made on retrospective patient recall, which is known to be significantly inaccurate for pain intensity, dietary composition, and medication timing.

3.2 PERT Underutilization and Suboptimal Dosing

Exocrine pancreatic insufficiency affects the majority of chronic pancreatitis patients, yet studies consistently demonstrate that PERT is significantly underdiagnosed, underprescribed, and — when prescribed — suboptimally dosed. Current clinical guidance recommends titrating lipase units based on fat content per meal (500–2,500 units per gram of fat), yet no structured tool exists to help patients or clinicians track dosing outcomes against fat intake over time. Dose adjustments are typically made based on patient-reported steatorrhea symptoms at appointments, an inherently imprecise and delayed feedback mechanism.

3.3 Absence of Disease-Specific Digital Tools

Existing digital health tools for digestive conditions target IBS, IBD, or general nutrition. No commercially available patient-facing platform addresses the specific management needs of pancreatitis: fat threshold tracking, enzyme dosing, flare pattern analysis, severe episode logging, or integrated physician communication with verified clinical identity.

3.4 Care Fragmentation

Pancreatitis patients frequently interface with gastroenterologists, pain management specialists, dietitians, endocrinologists (for type 3c diabetes), and primary care physicians. Communication between these providers and the patient is largely uncoordinated. Clinical notes from one provider are rarely visible to another, and the patient is left to synthesize and report their own care history — often incompletely.

5PancreaTrack AI — Platform Overview

PancreaTrack AI is a web-based digital health platform accessible from any device. It operates on a patient-facing application layer and a verified physician portal, connected through a secure, consent-based data-sharing architecture.

6Core Clinical Features

5.1 Pain Logging with Clinical Granularity

Patients log pain on a 0–10 numeric rating scale with timestamping, anatomical location (epigastric, left upper quadrant, diffuse, etc.), radiation pattern, and associated symptoms. The platform captures whether pain is associated with recent meals, enzyme intake, or activity. This granularity produces structured longitudinal pain data that directly supports clinical decision-making and mirrors validated pain assessment instruments used in gastroenterology research.

5.2 Dietary Tracking with Fat-Centric Analysis

Unlike general nutritional tracking applications that focus on caloric balance, PancreaTrack AI is architected around fat gram monitoring — the single most clinically relevant dietary variable in pancreatitis management. The platform integrates with the USDA FoodData Central database, providing access to over 1.1 million food items with validated macronutrient profiles. An AI-powered meal photo analysis feature allows patients to log meals by photograph, generating an automatic nutritional estimate with a pancreatitis-specific risk score based on fat content.

5.3 Severe Episode Tracking

Episodes with a pain score of 7 or greater are automatically flagged as severe and presented separately in both the patient dashboard and physician clinical view. Each severe episode record includes timestamp, pain score, location, duration, accompanying symptoms, and any notes. This creates an auditable log of high-acuity events that is invaluable for insurance documentation, disability assessment, and clinical treatment planning.

5.4 Food Tolerance Registry

Patients maintain a personalized food tolerance record — categorizing foods as well tolerated, neutral, or poorly tolerated based on their direct experience. This patient-generated dataset, when combined with corresponding fat content and pain data, represents a type of n-of-1 nutritional phenotyping that has not previously been accessible to clinicians outside of dedicated research settings.

5.5 Trend Visualization and Longitudinal Analysis

5.6 Doctor-Ready Report Generation

Pro-tier patients can generate comprehensive clinical summary reports in PDF format, presenting their pain data, dietary patterns, severe episodes, enzyme logs, and food tolerance profile in a format designed for clinical review. These reports reduce appointment preparation time for both patient and clinician and provide a standardized data structure for specialist referral documentation.

7The PERT Enzyme Tracker

The PERT Enzyme Tracker is the most clinically distinctive feature of PancreaTrack AI and represents a capability with no known equivalent in any currently available consumer or clinical digital health tool.

6.1 How the Optimizer Works

For each meal, the patient logs four data points: the fat content of the meal (grams), the enzyme brand taken, the total lipase units consumed, and a post-meal outcome rating on a five-point scale ranging from Great (no symptoms, well digested) to Bad (significant steatorrhea, diarrhea, or pain).

The platform then applies a nearest-neighbour analysis across all recorded successful doses (outcome rated Good or Great) to generate personalized dosing recommendations stratified by fat content range:

When insufficient personal data exists in a given fat range, the platform falls back to a conservative standard guideline dose (1,500 units/gram of fat) and clearly communicates this to the patient. The system also computes a personal units-per-gram ratio based on all successful doses, providing a clinically interpretable summary metric analogous to a patient's effective therapeutic dose.

6.2 Clinical Relevance

The PERT Enzyme Tracker addresses a critical and unmet need in EPI management. Current standard of care requires clinicians to adjust PERT doses based on patient-reported symptom response over multiple appointments — a slow and imprecise feedback loop that can leave patients undertreated for months. The Tracker builds a real-world evidence base of dose and outcome data at the meal level, giving the clinician an objective longitudinal record to reference at any appointment.

6.3 Scatter Visualization

An interactive scatter chart plots each logged dose as a point with fat intake on the x-axis, lipase units on the y-axis, and color-coding by outcome (green for good/great, amber for neutral, red for poor/bad). This visualization frequently reveals dose-response patterns that are not apparent from verbal patient reporting — for example, a patient taking adequate units for a 20g fat meal but consistently undermedicated for meals exceeding 30g.

8Verified Physician Portal & Care Coordination

7.1 NPI Verification at Registration

Physician access to PancreaTrack AI requires verification against the CMS NPPES National Provider Identifier Registry at the point of account creation. The platform queries the public NPPES API in real time, confirming that the registrant holds an active individual NPI (NPI-1), and auto-populates their name, credential, and specialty from the registry response. This ensures that only licensed, active individual healthcare providers can access the physician portal and patient clinical data — a meaningful safeguard that distinguishes PancreaTrack AI from platforms that rely on self-attestation.

7.2 Consent-Based Patient Access

Physician linking is fully physician-initiated: the provider enters the patient's registered email address in the Physician Portal to send a connection request. The patient receives an immediate in-app notification — surfaced in the bell notification panel and on their Profile page — showing the requesting physician's name, NPI-verified credentials, and specialty. The patient may approve or decline the request. Access is granted only upon explicit patient approval; there is no administrative override. Patients may revoke physician access at any time from Profile → Connected Providers, terminating data access immediately.

7.3 Clinical Dashboard View

The physician's patient view presents a structured clinical dashboard including:

• Key performance indicators: 7-day and 30-day average pain scores, severe episode count, total pain logs, average fat intake, and high-fat meal frequency — all presented as colored metric cards with clinical context.
• Individual severe episode log: each episode with pain score, location, associated notes, and timestamp.
• Fat intake trend chart (90 days) alongside pain score overlay — enabling visual correlation assessment.
• Food tolerance profile: categorized as tolerated, neutral, and intolerable — presented as a clinically scannable summary.
• Enzyme dose history: full PERT log with fat content, units taken, timing, and outcome for each entry.
• Current medications on record.

7.4 Bidirectional Care Note Threading

Physicians author structured clinical notes directly within the portal, categorized by type: General, Medication Update, Dietary Guidance, Follow-Up, or Urgent. Notes are immediately delivered to the patient with a bell notification in the application header and stored in a Care Notes inbox. Crucially, this is a bidirectional channel: patients can reply directly to any note, and their reply is surfaced to the physician with an unread badge on the physician dashboard. Physicians can then respond again, creating a full asynchronous conversation thread anchored to a specific clinical topic. All messages are timestamped, sender-attributed, and persist in the patient's care record. Email notifications are dispatched on each new message in the thread (patient preference, opt-out available), ensuring no communication is missed between appointments.

7.5 Physician AI Patient Brief

Immediately above each patient's clinical dashboard, a dedicated AI Brief panel allows the reviewing physician to generate a Gemini Pro clinical summary at the click of a button. The brief orients the physician to the patient's current status, flags data-backed concerns, and surfaces suggested appointment questions — all derived from the patient's actual logged data. See Section 9.4 for full technical detail.

7.6 Report Request — AI Clinical Query Engine (Beta)

The Report Request feature allows verified physicians to submit a plain-language clinical question about any linked patient and receive a fully structured AI-generated report in seconds. The physician types a natural-language query — such as "Show me enzyme dose vs. bowel outcomes over the past 14 days" or "What foods appear to correlate with high pain scores this month?" — and the system pulls the relevant longitudinal datasets, constructs a structured Gemini AI prompt, and returns a clinical narrative, a key findings list, and up to two auto-generated Chart.js visualizations.

All data is sourced directly from the patient's logged record — pain scores, meal logs, enzyme logs, bowel logs, and lab values. The AI does not fabricate or infer data not present. The system automatically parses time ranges from the query (days, weeks, or months, defaulting to 30 days), enforces a 365-day maximum window, and returns the total data point count alongside the report for clinical interpretability. Reports are printable as clean, standalone clinical documents suitable for inclusion in patient files.

Report Request represents an advancement from structured dashboards to dynamic clinical intelligence — allowing the physician to ask questions the dashboard was not designed to answer, without requiring any data export, manual correlation, or third-party analytics tool.

9AI-Powered Feature Suite

PancreaTrack AI integrates Google Gemini 2.5 (both Flash and Pro variants) across six distinct, purpose-built clinical AI features. Each feature is grounded in real patient data, produces structured clinical outputs, and operates with disease-specific context — not generic health AI. This represents a qualitative leap beyond symptom-logging apps that apply off-the-shelf AI to general health queries.

9AI-Powered Feature Suite (continued)

9.1 AI Meal Photo Analysis — Gemini Vision

Patients photograph any meal — at home, in a restaurant, at a social event — and receive an instant AI-generated nutritional breakdown within seconds. The feature uses Gemini 2.5 Flash's multimodal vision capability to identify every food item visible in the image, estimate macronutrients for the actual portion shown, and calculate a pancreatitis-specific dietary risk score from 0 to 100.

When AI analysis succeeds, identified foods auto-populate the meal log and serve as the primary nutritional data source, with USDA FoodData Central and manual entry available as fallbacks. For Pro subscribers, AI meal scanning is unlimited. Basic (free) subscribers receive two AI scans per week — providing a meaningful taste of the feature while incentivizing plan upgrade.

9.2 AI Trigger Finder — Gemini Flash (Pro)

The Trigger Finder is the platform's most analytically complex patient-facing AI feature. It performs a structured 90-day meal-pain correlation analysis, examining every meal logged within a 0.5–8 hour window before each pain episode and aggregating findings by food item, fat content range, and pain outcome.

The system identifies foods appearing in at least two pre-pain events, calculates an average pain multiplier (the ratio of post-consumption pain score to the patient's baseline), and classifies findings by confidence level (High / Moderate / Low) based on occurrence frequency. This structured dataset is sent to Gemini 2.5 Flash alongside a full 90-day pain and meal statistical summary, and the model returns:

• Trigger list: Each identified food with evidence count, average pain impact, confidence level, and a specific dietary recommendation.
• High-fat vs. low-fat pain comparison: Quantified difference in average pain scores between high-fat (>20g) and low-fat meals, establishing the patient's fat sensitivity.
• Narrative insight: A two-to-three sentence clinical synthesis of the patient's overall dietary trigger pattern and actionable take-away.
• Data quality flag: Honest assessment of whether the data volume is sufficient to support reliable conclusions.

9.3 Pre-Appointment Summary — Gemini Pro (Pro)

Before any scheduled appointment, Pro subscribers can generate a structured, physician-ready clinical narrative summarizing their health status over a selected 30, 60, or 90-day window. The summary is designed to be printed or copied directly to a patient portal message and handed to the clinician at appointment check-in.

The AI synthesizes pain statistics, dietary data, severe episode frequency, trend direction (improving / stable / worsening — computed by comparing the first and second halves of the selected window), food tolerance patterns, and any physician care notes received. Gemini 2.5 Pro then generates a structured clinical document comprising:

The generated document includes a print stylesheet that removes all application chrome, producing a clean clinical summary page. A one-click clipboard copy function supports direct paste into patient portal messages. Results are cached per period window for six hours, eliminating redundant API calls on repeat views.

9.4 Physician AI Patient Brief — Gemini Pro

This feature operates within the physician portal and generates a structured clinical brief from the physician's perspective before they review or see a patient. It pulls the full patient dataset — demographics, pain statistics (30 and 90-day), meal logs, food tolerance records, physician care notes from the prior 60 days, and current medications — and submits it to Gemini 2.5 Pro with a clinical framing prompt authored around pancreatitis-specific concerns.

The returned brief is rendered in a structured panel within the physician's patient view and includes:

The brief is cached per physician-patient pair for six hours, ensuring rapid loading on repeat views without redundant API consumption. Physicians can regenerate on demand to refresh the analysis. The brief prints cleanly alongside the patient's clinical data for use in paper-based workflows.

9.5 Document Q&A — Gemini Pro (Basic & Pro)

Patients routinely receive complex clinical documents — laboratory panels, radiology reports, discharge summaries, operative notes — that are written in clinical terminology inaccessible to most patients. The resulting comprehension gap drives unnecessary anxiety, poor self-management, and inefficient appointment time spent on explanations that could have been addressed in advance.

The Document Q&A feature allows patients to upload PDFs, photos, or scans of medical documents directly within the PancreaTrack application. Gemini 2.5 Pro reads the full document — including multimodal content such as images within PDFs — and generates a structured, patient-facing analysis comprising:

Supported document types include laboratory results, radiology and imaging reports (CT, MRI, MRCP, ultrasound), hospital discharge summaries, and operative or procedure notes. Accepted file formats are PDF, JPEG, PNG, and WebP up to 10 MB per upload.

The feature carries a prominent disclaimer throughout the interface: Document Q&A is an educational translation tool only — it does not provide clinical interpretation, diagnosis, or treatment guidance, and patients are explicitly directed to discuss all findings with their physician. Basic plan users receive three document analyses per calendar month; Pro plan users have unlimited uploads with persistent history.

10Data Privacy, Security & Compliance

9.1 Encryption and Access Control

All data transmitted between patients, physicians, and the PancreaTrack AI platform is encrypted in transit via TLS 1.2 or higher. Stored health data is encrypted at rest. Session management employs separate, isolated authentication namespaces for patients, physicians, and administrative users to prevent cross-role access. All physician portal access events are captured in a comprehensive audit log recording the physician ID, patient accessed, action performed, and timestamp — providing a complete, tamper-evident access record suitable for compliance review.

9.2 Physician Identity Verification

Physician access to PancreaTrack AI requires a two-layer identity verification process. First, the registrant's NPI is verified in real time against the CMS NPPES National Provider Identifier Registry, confirming an active individual provider license. Second, government-issued photo ID verification is performed via Stripe Identity — confirming that the individual registering is the actual person to whom the NPI belongs. This dual-layer verification closes the impersonation gap present in platforms relying on NPI self-attestation alone, and represents a meaningful safeguard for patient data access.

9.3 Consent Architecture

Patient-to-physician data access is governed entirely by explicit patient consent. Tokens are time-limited to seven days, single-use in their sharing context, and revocable at any point by the patient. No physician can query or access patient data without a valid, patient-issued token. No data is shared with third parties for advertising or commercial profiling purposes.

9.4 Compliance Posture

PancreaTrack MedTech LLC has executed a Business Associate Agreement (BAA) with Amazon Web Services and is actively migrating platform infrastructure to HIPAA-eligible AWS services — including Amazon RDS with encryption at rest, Amazon S3 for document storage, CloudTrail audit logging, and VPC network isolation. Current security controls include TLS encryption in transit, role-based access control, NPI + government ID physician verification, patient consent gating, physician audit logging, and PCI-compliant payment processing via Stripe. Full HIPAA compliance attestation is targeted for 2026–2027.

11Research Partnership Opportunities

PancreaTrack AI represents a novel data collection infrastructure for pancreatitis research. The platform is uniquely positioned to support the following research domains:

10.1 PERT Dosing Outcomes Research

Aggregate, de-identified enzyme log data — correlating lipase unit doses, fat content, enzyme brand, and patient-reported outcome — constitutes a dataset with no existing equivalent in published literature. A multi-site outcomes study examining real-world PERT dosing patterns and their relationship to steatorrhea symptoms and quality of life could yield clinically actionable findings relevant to EPI management guidelines.

10.2 Dietary Trigger Characterization

The combination of food-level fat data, pain scores, and food tolerance records across a large patient cohort provides an opportunity to characterize individual and population-level fat threshold patterns in pancreatitis. This has direct implications for dietary guideline development, which currently relies on expert consensus rather than patient-derived data.

10.3 Readmission Prevention

Longitudinal pain trend data in the days preceding documented severe episodes — including patterns that precede emergency department visits or hospitalizations — could be used to train and validate a readmission risk prediction model. Such a model could be integrated into the platform's alert system to reduce preventable hospitalizations in high-risk patients.

10.4 Quality Improvement in Gastroenterology Practice

Practices that enroll their pancreatitis patient panels on PancreaTrack AI gain structured, longitudinal outcome data that can support clinical quality improvement reporting, value-based care metrics, and demonstration of patient engagement — increasingly relevant in outcomes-based reimbursement models.

12Comparative Landscape

12.1 Limitations of Existing Pancreatic Health Tools

The digital health market is large and growing. Hundreds of thousands of health applications are available across major platforms, and the chronic disease management segment attracts significant investment and clinical attention. Yet for patients with pancreatitis, this abundance of tools has not translated into meaningful support. The market exists — the clinical need is documented, the patient population is real, and the cost burden is measurable. What has not existed is a solution designed specifically for this condition.

The tools patients typically encounter fall into three broad categories. Each addresses one dimension of the problem. None address the condition as a whole.

General Nutrition & Calorie Tracking Apps

Applications in this category — including widely used platforms built around food logging and macronutrient tracking — provide meaningful utility for weight management and general dietary awareness. For pancreatitis patients, however, they fall short in several critical respects. They are architecturally neutral with respect to disease: a gram of fat is treated identically whether the user is an athlete managing body composition or a patient whose pancreas cannot tolerate high-fat intake without triggering a pain episode.

These platforms do not capture pain, enzyme doses, or post-meal outcomes. They cannot correlate dietary patterns with symptom data because they do not collect symptom data. They have no mechanism to surface food-specific risk based on clinical context, no physician-facing view, and no infrastructure for care coordination. A patient using a general nutrition app to manage pancreatitis is using a tool designed for a fundamentally different purpose — and the absence of disease-aware logic means that critical clinical signals go uncaptured and uncommunicated.

General GI and Chronic Illness Symptom Trackers

A second category of tools targets digestive health or general chronic illness symptom tracking. These platforms are meaningfully more relevant than general nutrition apps: they capture symptom data, support longitudinal logging, and in some cases include trend visualization. However, they are designed around conditions with different clinical architectures — primarily irritable bowel syndrome and inflammatory bowel disease — and this design assumption is embedded in their data models, risk logic, and clinical outputs.

The clinical management of pancreatitis differs from IBS and IBD in important ways. Enzyme replacement therapy (PERT) is central to EPI management and has no equivalent in IBS or IBD care pathways. Fat gram thresholds — not general dietary restriction — are the primary dietary variable in pancreatitis. Type 3c diabetes, a complication unique to pancreatic disease, requires glucose monitoring integration that general GI apps do not contemplate. None of the currently available GI-focused applications track lipase units against fat content, none calculate personalized PERT dosing recommendations from longitudinal outcome data, and none are built around the clinical vocabulary of pancreatitis — steatorrhea, EPI, flare severity, enzyme efficacy — that defines the patient’s daily experience.

The result is a category of tools that is adjacent to what pancreatitis patients need, but not sufficient. Patients may adapt these tools to their use case — logging “flares” as generic symptoms, using free-text fields for enzyme notes — but they are working around the tool’s design, not with it. The clinical intelligence that would make these logs actionable simply is not present.

EHR Patient Portals and General Health Platforms

Electronic health record patient portals represent a third category. These platforms provide valuable access to test results, appointment scheduling, and provider messaging, and they serve an important function in the broader care ecosystem. What they do not provide is active, structured, longitudinal symptom capture between appointments. They are repositories for clinical documentation generated by the healthcare system — not tools for the patient to generate structured health data in the intervals between visits.

The distinction matters because the clinical data problem in pancreatitis management is precisely an between-appointment problem. A portal that surfaces a patient’s most recent lipase result does not help a clinician understand how that patient’s pain scores have trended over the prior 90 days, which meals preceded their last three flares, or whether their current PERT dose is controlling steatorrhea. That data does not exist in the EHR — because no structured mechanism exists to collect it. General health platforms and wearable integrations provide activity, sleep, and heart rate data but lack the clinical specificity required for pancreatitis management: the GI-specific symptom vocabulary, the fat-centric dietary framework, the enzyme dosing infrastructure.

The Gap That Remains

Across all three categories, the same structural gaps recur: no PERT tracking, no fat–pain correlation engine, no pancreatitis-specific risk scoring, no verified physician access layer, and no AI capabilities built around the clinical context of the disease. These are not features that can be approximated by configuring a general tool differently. They require a purpose-built architecture — one in which the disease model is embedded in the data schema, the logic, and the clinical outputs from the ground up.

This is the gap PancreaTrack AI was built to fill. It is not a gap that exists because the market is too small or the clinical need is unclear. It exists because building a disease-specific platform requires deep alignment with the clinical realities of a specific condition — and that work has not previously been done for pancreatitis. The following table illustrates where currently available platforms stand against the clinical requirements of this patient population:

13Business Model & Platform Valuation

13Business Model & Platform Valuation (continued)

13.1 Revenue Architecture

PancreaTrack AI operates on a freemium SaaS model with two consumer tiers and a forthcoming institutional pathway. The free Basic tier drives top-of-funnel user acquisition by delivering core logging features at no cost. The Pro tier ($9.99/month or $99.99/year) unlocks the full AI feature suite, unlimited meal photo scanning, the Trigger Finder, Pre-Appointment Summary, and advanced trend analytics. Physicians access the portal and AI Brief tool at no cost — a deliberate strategy to maximize physician adoption as the primary patient referral channel.

13.2 Total Addressable Market

The US chronic pancreatitis patient population is estimated at approximately 285,000 adults (86 per 100,000), with an additional annual incidence of over 300,000 acute pancreatitis hospitalizations — a significant portion of which progress to recurrent or chronic disease. Digital health adoption rates among chronic condition patients currently sit at 30–40%, yielding a US serviceable addressable market of approximately 85,000–115,000 patients for a platform of this specificity.

Globally, chronic pancreatitis prevalence in developed markets (EU, UK, Canada, Australia) adds an estimated additional 600,000–800,000 addressable patients, bringing the total global SAM to approximately 700,000–900,000 once international expansion is considered.

13.3 AI Features as the Pro Conversion Engine

The introduction of five distinct Gemini AI capabilities materially strengthens the Pro value proposition. In digital health SaaS, AI-powered personalization is the single strongest driver of free-to-paid conversion. Meal photo scanning — visible immediately on the logging screen with a weekly scan limit for free users — creates a direct, recurring "upgrade moment" every time a free user photographs a meal and hits their limit. The Trigger Finder and Pre-Appointment Summary are premium-only features with immediately obvious clinical utility, creating pull-through upgrade motivation at appointment cycles (typically monthly).

13.4 Revenue Projections

Note: Projections reflect consumer subscription revenue only and exclude institutional licensing, research data agreements, and physician practice partnerships. SaaS multiples reflect 2025–2026 comparable public company medians for health tech SaaS (source: SaaS Capital, Bessemer Cloud Index).

13.5 Physician Network Effect & Revenue Multiplier

The physician portal introduces a powerful network effect absent in most consumer health apps: each physician who adopts PancreaTrack AI into their practice becomes an active referral source for the platform. A single gastroenterologist managing 200 pancreatitis patients who recommends the platform to their panel creates a direct pipeline of 200 potential subscribers. This B2C-through-B2B model — free physician tools as a patient acquisition channel — significantly reduces customer acquisition cost (CAC) relative to direct consumer digital marketing.

A future institutional licensing tier — practice-level subscriptions granting physicians enhanced analytics dashboards, aggregate patient cohort views, and custom report generation — represents an incremental B2B revenue layer estimated at $299–$599/month per practice, with hospital system partnerships in the $10,000–$50,000/year range for multi-specialty deployments.

13.6 Comparable Benchmark Valuations

14Conclusion & Call to Action

PancreaTrack AI addresses a genuine and significant unmet need in pancreatitis care. By placing structured, continuous, disease-specific health data in the hands of both patients and their verified clinicians, the platform has the potential to meaningfully improve the quality of care between appointments, reduce the diagnostic inefficiency created by recall-based symptom reporting, and generate a dataset of real-world pancreatitis outcomes that does not currently exist at scale.

We invite gastroenterologists, GI practice groups, academic medical centers, and research institutions to explore the following partnership pathways:

• Clinical recommendation: Recommend PancreaTrack AI to your pancreatitis patient panel as a structured self-management and monitoring tool. Free and Pro tiers are available, with no cost to the physician or institution.
• Physician portal enrollment: Register your practice on the physician portal to receive structured clinical data from consenting patients ahead of appointments — reducing appointment overhead and improving data quality.
• Research collaboration: Partner with us to design and execute outcomes studies using de-identified platform data. IRB-ready data sharing protocols and research use agreements are available.
• Quality improvement programs: Integrate PancreaTrack AI into your practice's value-based care and patient engagement initiatives, with aggregate outcome reporting available for QI documentation.
• Feedback and clinical advisory: We actively seek clinical input to ensure the platform's features, metrics, and insights align with current evidence-based pancreatitis management guidelines.

15References

1. Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: Update 2018. Gastroenterology. 2019;156(1):254–272.
2. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144(6):1252–1261.
3. Whitcomb DC, Frulloni L, Garg P, et al. Chronic pancreatitis: An international draft consensus proposal for a new mechanistic definition. Pancreatology. 2016;16(2):218–224.
4. Löhr JM, Dominguez-Munoz E, Rosendahl J, et al. United European Gastroenterology evidence-based guidelines for the diagnosis and treatment of chronic pancreatitis. United European Gastroenterology Journal. 2017;5(2):153–199.
5. Frulloni L, Falconi M, Gabbrielli A, et al. Italian consensus guidelines for chronic pancreatitis. Digestive and Liver Disease. 2010;42(Suppl 6):S381–S406.
6. Domínguez-Muñoz JE, Iglesias-García J. Oral pancreatic enzyme substitution therapy in chronic pancreatitis: Is clinical response an appropriate marker for evaluation of therapeutic efficacy? JOP. 2010;11(3):158–162.
7. Jalal M, Campbell JA, Hopper AD. Practical guide to the management of chronic pancreatitis. Frontline Gastroenterology. 2019;10(3):253–260.
8. Afghani E, Sinha A, Singh VK. An overview of the diagnosis and management of nutrition in chronic pancreatitis. Nutrition in Clinical Practice. 2014;29(3):295–311.
9. Ewald N, Bretzel RG. Diabetes mellitus secondary to pancreatic diseases (type 3c): Are we missing an etiologically specific diagnosis? Diabetes/Metabolism Research and Reviews. 2013;29(5):333–336.
10. Hart PA, Bellin MD, Andersen DK, et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. The Lancet Gastroenterology & Hepatology. 2016;1(3):226–237.
11. Machicado JD, Yadav D. Epidemiology of recurrent acute and chronic pancreatitis: Similarities and differences. Digestive Diseases and Sciences. 2017;62(7):1683–1691.
12. de-Madaria E, Abad-González A, Aparicio JR, et al. The Spanish Pancreatic Club's recommendations for the diagnosis and treatment of chronic pancreatitis: Part 2 (treatment). Pancreatology. 2013;13(1):18–28.
13. Drewes AM, Bouwense SAW, Campbell CM, et al. Guidelines for the understanding and management of pain in chronic pancreatitis. Pancreatology. 2017;17(5):720–731.
14. Olesen SS, Juel J, Graversen C, et al. Pharmacological pain management in chronic pancreatitis. World Journal of Gastroenterology. 2013;19(42):7292–7301.
15. Pham A, Forsmark C. Chronic pancreatitis: Review and update of etiology, risk factors, and management. F1000Research. 2018;7:F1000 Faculty Rev-607.
16. IQVIA Institute for Human Data Science. Digital Health Trends 2021: Innovation, Evidence, Regulation, and Adoption. IQVIA; 2021.
17. Pew Research Center. Mobile Fact Sheet. Washington, DC: Pew Research Center; 2023. Available at: pewresearch.org/internet/fact-sheet/mobile/
18. Accenture. 2020 Digital Health Consumer Survey. Accenture; 2020.
19. Stone AA, Schwartz JE, Broderick JE, Shiffman S. Variability of momentary pain predicts recall of weekly pain: A consequence of the peak (or salience) memory heuristic. Personality and Social Psychology Bulletin. 2005;31(10):1340–1346.
20. Deloitte. 2022 Global Health Care Outlook: Are we finally seeing the long-promised transformation? Deloitte Insights; 2022.
21. Rock Health. 2022 Digital Health Consumer Adoption Report. Rock Health; 2022.